Enzyme activatable photodynamic therapy agents targeting melanoma
Imran Verirsen1, Busra Uyar1, Nezahat Gokce Ozsamur1
1Konya Food and Agriculture University, Faculty of Science, Department of Biotechnology, 42080, Konya, Turkey. sundus.erbascakmak@gidatarim.edu.tr.
Organic & Biomolecular Chemistry
|November 7, 2022
Summary
Researchers developed a novel pyridinium BODIPY photosensitizer for targeted cancer therapy. This tyrosinase-activated compound selectively kills melanoma cells, showing promise for personalized treatments with reduced side effects.
Area of Science:
- Biochemistry
- Organic Chemistry
- Photodynamic Therapy
Background:
- Targeted drug delivery is crucial for effective cancer treatment with minimal side effects.
- Developing activatable photosensitizers offers a strategy for localized therapeutic action.
Purpose of the Study:
- To develop and characterize a novel, structurally simple pyridinium BODIPY-based photosensitizer.
- To investigate its tyrosinase-activatable properties and singlet oxygen generation capacity.
- To evaluate its potential for cell-selective photodynamic therapy.
Main Methods:
- Synthesis of a pyridinium BODIPY-based photosensitizer.
- Analysis of singlet oxygen quantum yields for active and inactive forms.
- Assessment of selective photo-induced cell death in various cancer cell lines (melanoma, mammary, hepatocellular carcinoma).
Main Results:
- The developed photosensitizer is tyrosinase-activatable.
- Singlet oxygen quantum yields were determined to be 0.64 for the active form and 0.02 for the inactive form.
- Selective photo-induced cell death was observed in mouse melanoma cells compared to mammary and hepatocellular carcinoma cells.
Conclusions:
- A novel pyridinium BODIPY photosensitizer with tyrosinase-activatable properties has been successfully developed.
- The photosensitizer demonstrates efficient singlet oxygen generation upon activation.
- This compound shows significant potential for tissue-selective photodynamic therapy, particularly against melanoma.
